Anti-Giardia Drug Discovery: Current Status and Gut Feelings
| Autor: | Tina S. Skinner-Adams, Christopher J.S. Hart, Katharine R. Trenholme, Andrew G. Riches |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0303 health sciences
medicine.medical_specialty biology Chemistry Drug discovery Giardia Enteric pathogen Drug resistance biology.organism_classification Antimicrobial 01 natural sciences Giardia Infections 0104 chemical sciences 010404 medicinal & biomolecular chemistry 03 medical and health sciences Pharmacotherapy parasitic diseases Drug Discovery medicine Molecular Medicine Health education Intensive care medicine 030304 developmental biology |
| Zdroj: | Journal of Medicinal Chemistry. 63:13330-13354 |
| ISSN: | 1520-4804 0022-2623 |
| Popis: | Giardia parasites are ubiquitous protozoans of global importance that impact a wide range of animals including humans. They are the most common enteric pathogen of cats and dogs in developed countries and infect ∼1 billion people worldwide. While Giardia infections can be asymptomatic, they often result in severe and chronic diseases. There is also mounting evidence that they are linked to postinfection disorders. Despite growing evidence of the widespread morbidity associated with Giardia infections, current treatment options are limited to compound classes with broad antimicrobial activity. Frontline anti-Giardia drugs are also associated with increasing drug resistance and treatment failures. To improve the health and well-being of millions, new selective anti-Giardia drugs are needed alongside improved health education initiatives. Here we discuss current treatment options together with recent advances and gaps in drug discovery. We also propose criteria to guide the discovery of new anti-Giardia compounds. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|